February Featured Cancer Clinical Trials

SWOG 1222
Disease: Breast
Objective: The primary objective is to test the benefit of interfering with the function of the estrogen receptor (ER) and providing downstream target inhibition (PI3K/AKT/mTOR) with a combination of optimal dose fulvestrant and everolimus (Arm 2) to improve progression-free survival compared to the optimal dose fulvestrant alone (Arm 1).

CLVS 1514
Disease: NSCLC (Non-small cell lung cancer)
Objective: The primary objective is to evaluate the antitumor efficacy of oral (PO) single agent CO-1686 , as measured by ORR, when administered to patients with EGFR-mutated,T790M positive, advanced NSCLC after tumor progression on 1 previous EGFR-directed TKI.

MDCC 1914
Disease: Myelodysplastic Syndrome (MDS)
Objective: The primary objective is to compare the event-free survival rates of two different drugs: DAC versus AZA on an abbreviated schedule to a standard arm of AZA given over 5 days in patients with low-risk MDS transfusion-dependent and to BSC in patients with low-risk MDS transfusion-independent.

ESAI 1314
Disease: Thyroid
Objective: The primary objective is to provide lenvatinib with a starting dose of either 24-mg, 20-mg, or 14-mg/day to subjects with RR-DTC who have failed the available standard of care treatment, have no other treatment options, and therapy is requested by their physician.

METH 1814
Disease: Bladder, Genitourinary, Urethral
Objective: The primary objective is to determine the efficacy of mocetinostat in patients with locally advanced, unresectable or metastatic urothelial carcinoma who have inactivating mutations or deletions involving CREBBP and/or EP300 gene loci in their tumor tissue.

SWOG 1314
Disease: Bladder
Objective: The primary objective is to characterize the relationship of DDMVAC- and GC-specific COXEN scores in terms of pT0 rate at cystectomy in patients treated with neoadjuvant chemotherapy.

INFT 1314
Disease: Brain Glioblastoma
Objective: The primary objective is to investigate by MR imaging the spatial and temporal distribution of topotecan in tumor and tumor-infiltrated brain administered by convection-enhanced delivery (CED) in patients with recurrent/progressive WHO grade III or IV (high grade) glioma (HGG) who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.

SWOG 1312
Disease: Leukemia, Acute Lymphoblastic (ALL), Acute Myeloid (AML)
Objective: The primary objective is to assess the safety of inotuzumab ozogamicin in combination with cyclophosphamide, vincristine and prednisone (CVP) and to determine the maximum tolerated dose (MTD) of inotuzumab ozogamicin in this regimen for patients with relapsed or refractory CD22+ acute leukemia (B-ALL, mixed phenotype, and Burkitt’s).